Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease

Inflammatory bowel disease(IBD) is a chronic relapsing disease in gastrointestinal tract. Conventional medications lack the efficacy to offer complete remission in IBD therapy,and usually associate with serious side effects. Recent studies indicated that nanoparticle-based nanotherapeutics may offer...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG 2016-09, Vol.22 (34), p.7718-7726
Main Authors: Si, Xiao-Ying, Merlin, Didier, Xiao, Bo
Format: Article
Language:English
Subjects:
Administration, Oral
administration
Nanotherapeutic
Cell
Animals
bowel
Cell Nucleus - metabolism
disease
Drug Carriers - chemistry
Endosomes - metabolism
Epithelium - metabolism
Fusion Regulatory Protein-1 - chemistry
Galactose - chemistry
Gastrointestinal Tract - drug effects
Humans
Hyaluronic Acid - chemistry
Hydrogels - chemistry
Hydrogen-Ion Concentration
Inflammatory Bowel Diseases - therapy
Mannose - chemistry
Nanoparticles - chemistry
Oral
Permeability
Pharmaceutical Preparations - administration & dosage
Reactive Oxygen Species - metabolism
Receptors, Transferrin - chemistry
Review
specificity
Inflammatory
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inflammatory bowel disease(IBD) is a chronic relapsing disease in gastrointestinal tract. Conventional medications lack the efficacy to offer complete remission in IBD therapy,and usually associate with serious side effects. Recent studies indicated that nanoparticle-based nanotherapeutics may offer precise and safe alternative to conventional medications via enhanced targeting,sustained drug release,and decreased adverse effects. Here,we reviewed orally cell-specific nanotherapeutics developed in recent years. In addition,the various obstacles for oral drug delivery are also reviewed in this manuscript. Orally administrated cell-specific nanotherapeutics is expected to become a novel therapeutic approach for IBD treatment.
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v22.i34.7718